US 11,952,575 B2
Transaminase mutant and use thereof
Hao Hong, Tianjin (CN); Gage James, Tianjin (CN); Jiangping Lu, Tianjin (CN); Xingfu Xu, Tianjin (CN); Wenyan Yu, Tianjin (CN); Xin Huang, Tianjin (CN); Yulei Ma, Tianjin (CN); and Yibing Cheng, Tianjin (CN)
Assigned to ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD, Tianjin (CN)
Appl. No. 16/652,291
Filed by Asymchem Life Science (Tianjin) Co., Ltd, Tianjin (CN)
PCT Filed Nov. 15, 2017, PCT No. PCT/CN2017/111161
§ 371(c)(1), (2) Date Mar. 30, 2020,
PCT Pub. No. WO2019/095161, PCT Pub. Date May 23, 2019.
Prior Publication US 2020/0239895 A1, Jul. 30, 2020
Int. Cl. C12N 9/00 (2006.01); C12N 15/70 (2006.01); C12P 13/00 (2006.01)
CPC C12N 15/70 (2013.01) [C12P 13/001 (2013.01); C12Y 206/01 (2013.01)] 6 Claims
 
1. A transaminase mutant, wherein the amino acid sequence of the transaminase mutant is the mutated amino acid sequence of SEQ ID NO: 1, and wherein the mutated amino acid sequence comprises mutations at one or more of amino acids selected from a group consisting of P243E, F89Y/W, K193E, V234I, I262V, Q280K, V379L/M/T, R416A/C/H/Q/T/S, A417S and C418A/Q/S, wherein “/” stands for “or”, and wherein the mutations at one or more of amino acids must comprise V379.